Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, ...

CAMBRIDGE, MA - A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine dose.In ...

Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell ...

Moderna (($MRNA)) has held its Q3 earnings call. Read on for the main highlights of the call. During Moderna’s recent earnings call, the sentiment ...

Moderna Inc (MRNA) navigates a challenging quarter with significant cost reductions and strategic partnerships, despite a decline in COVID vaccine demand.

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Australia's Victoria state on Wednesday unveiled plans to develop an onshore messenger-RNA (mRNA) vaccine manufacturing facility and launched three mass coronavirus immunisation centres to speed up ...